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Annotation. Parallel import of medicinal products is being defined as an import into 
the Republic of Lithuania outside the distribution network of the authorised distributor 
of the product granted marketing authorisation in another EEA Member State, which is 
identical to the medicinal product already granted marketing authorisation in the Republic 
of Lithuania or sufficiently resembling it. The majority of parallel import of medicinal 
products related cases in the Court of Justice of the European Union (hereinafter – CJEU) are 
dealing with barriers for parallel trade that occur in license issuance procedure. Therefore, 
the main goal of this article is to identify and analyse regulatory peculiarities of parallel 
import of medicinal products licence (hereinafter – parallel import licence or licence) 
issuance procedure that may create barriers for the parallel trade of medicinal products in 
the Republic of Lithuania. In order to achieve this task, the article evaluates the necessity of 
parallel import licence, analyses separate elements of this procedure, identifies its regulatory 
peculiarities and discusses whether these regulatory peculiarities are acceptable for the EU 
law.
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The article concludes that domestic law of the Republic of Lithuania creates challenges 
for a parallel trader, as the EU law and the CJEU jurisprudence were not taken into 
account during the implementation of sufficient similarity criteria. A lack of detailed 
secondary legislation together with administrative problems may reduce the accessibility of 
the procedure and challenge the implementation of the requirement of the CJEU that this 
procedure should last “a reasonable time”.
Keywords: parallel import, licence, medicinal products, pharmaceutical law, EU law. 
Introduction 
according to article 2 part 57 of the law on Pharmacy of the Republic of lithuania, 
parallel import of medicinal products means “import into the Republic of lithuania out-
side the distribution network of the authorised distributor of the product granted marke-
ting authorisation in another EEa member State, which is identical to the medicinal pro-
duct already granted marketing authorisation in the Republic of lithuania or sufficiently 
resembling it”1. The same definition of parallel import is used in the Eu law2. article 17 of 
the above mentioned law that took force in 2006 defines the main conditions for parallel 
import and licence issuance procedure. However, parallel import of medicinal products is 
still at the rudimental stage in lithuania. There are 229 medicinal products (this number 
includes variations) on the list of Parallel Import medicinal Products3. The number of 
legal entities operating in the aerie of parallel import of medicinal products is also very 
limited. 
on the other hand, it is problematic that parallel import of medicinal products 
is regulated by common norms of the primary Eu law only, i.e. the parallel import is 
based on article 34 (ex. 28) of the  treaty on the functioning of the European union4 
(hereinafter – tfEu) and is subject to the derogations regarding the protection of human 
health and life and the protection of industrial and commercial property, as defined by 
article 36 (ex. 30) of the tfEu. No special secondary legislation addresses the issue of 
parallel trade of medicinal products and the jurisprudence of the cjEu proofs that Eu 
member States differently interpret the primary law of the Eu and so create obstacles for 
parallel trade of medicinal products. There are several cases at the court of justice of the 
1 law on Pharmacy of the Republic of lithuania (translation) [interactive]. Vilnius, 2006 [accessed 
on 13-03-2013]. <http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=296798>. 
2 commission of the European communities, communication on Parallel Imports of 
Proprietary medicinal Products for which marketing authorisations Have already Been 
granted. com (2003) 839 final [interactive]; Brussels, 2003, 4 [accessed on 13-03-2013]. 
<http://eur-lex.europa.eu/lexuriServ/lexuriServ.do?uri=com:2003:0839:fIN:en:Pdf>.
3 Valstybinė vaistų kontrolės tarnyba prie lietuvos Respublikos Sveikatos apsaugos ministe-
rijos. lygiagrečiai platinamų lietuvos Respublikoje vaistinių preparatų sąrašas [interactive]. 
Vilnius, 2013 [accessed on 11-09-2013].  <http://i2.alfi.lt/46/68/81.jPg>.
4 treaty on the functioning of the European union (consolidated version). [2012] oj c326.
Mindaugas Zalepūga. Legal Requirements for Parallel Import of Medicinal Products ...1192
European union that are closely connected with domestic requirements of member States 
for parallel import licence issuance procedure5, 6, 7, 8, 9.
It may be hypothetically presumed that lithuanian regulation may also create barriers 
for parallel trade of medicinal products in lithuania that cannot be justified with the help 
of derogations defined in article 36 of the tfEu. These barriers may make parallel import 
less attractive for legal entities and lead to a smaller number of parallel import medicinal 
products than in neighbouring Eu countries with nearly the same pharmaceutical 
marked, e.g., there are 305 parallel import medicinal products (including variations) in the 
Register of Human medicines in latvia10. Respectively, questions may arise whether the 
current lithuanian regulation is economically well grounded and whether it corresponds 
to the officially declared aims of national pharmaceutical policy that identifies priorities, 
such as reduction of prices of medicinal products and improvement of access to medicinal 
products, as well11. meanwhile, parallel import, as such, is undoubtedly capable to achieve 
the above mentioned aims and current data show that the parallel trade industry has 
provided about 2.5 billion savings for member States during the period of 2004–2009 
and this trend is likely to be sustained in the future12, 13, 14. However, neither lithuanian 
regulation of parallel trade of medicinal products, nor the economic consequences of it 
have been systematically analysed in scientific works in lithuania15. 
5 case 104/75, de Peijper [1976] EcR 00613.
6 case 15/74, Centrafarm v Sterling Drug [1974] EcR 01147.
7 case c-112/02, Kohlpharma [2004] EcR I-03369.
8 case c-113/01, Paranova Oy [2003] EcR I-04243.
9 case c-212/03, Commission of the European Communities v French Republic [2005] EcR 
I-04213.
10 State agency of medicines of latvia. Register of Human medicines [interactive]. Riga, 2013 
[accessed on 13-03-2013]. <http://www.vza.gov.lv/index.php?id=375&top=334&oN=&IN=&
Ra=&PN=&RN=&m=0&atc=&P_u=&IN_c=&PI=1>. 
11 lietuvos Respublikos Seimo 2003 m. birželio 5 d. nutarimas Nr. IX-1604 „dėl lietuvos nacio-
nalinės vaistų politikos nuostatų patvirtinimo“. Valstybės žinios. 2003, Nr.56-2488. 
12 European association  of Euro-Pharmaceutical companies. €2.5 Billion: four Years of Parallel 
distribution Savings  for Europeans. Press Release. [interactive]. 23 january, 2012 [accessed on 
15-12-2012]. <http://www.eaepc.org/admin/files/130123_eaepc_press_release_final.pdf>.
13 grossman, g. m.; lai, E. c. l. Parallel Imports and Price controls. RAND Journal of Economics. 
2008, 39(2): 378–402.
14 Hostenkamp, g.; kronborg, k.; arendt, j. N. Parallel Imports of Hospital Pharmaceuticals: 
an Empirical analysis of Price Effects from Parallel Imports and the design of Procurement 
Procedures in the danish Hospital Sector. Discussion Papers on Business and Economics. 2012, 
16: 1–20.
15 Some articles have analysed individual issues related to the parallel import of medicinal products 
and, according to the author, they do not represent a systematic review. Eg., Širinskienė, a; 
Zalepūga, m.  Perpakavimo įtakos lygiagrečiai importuojamų vaistinių preparatų kokybei 
vertinimas Europos Sąjungos teisingumo teismo jurisprudencijoje. Sveikatos mokslai.  2011, 
1(73): 3854–3860.  Širinskienė, a.; Zalepūga, m. lygiagretaus patentinių vaistinių preparatų 
importo apribojimai lietuvos Respublikos stojimo sutartyje. Visuomenės sveikata.  2011, 1(52): 
42–49. Širinskienė, a.; Zalepūga, m. lygiagrečiai importuojamų vaistinių preparatų kainodaros 
reguliavimo problemos lietuvoje. Taikomieji tyrimai – visuomenės kaitai: mokslinių straipsnių 
rinkinys. 2011, 6: 128–135. 
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Therefore, the main object of this article is regulation of parallel import of medicinal 
products license issuance procedure. The goal of the article is to identify and analyse 
regulatory peculiarities of parallel import of medicinal products licence issuance 
procedure that may create barriers for the parallel trade of medicinal products in the 
Republic of lithuania. The following tasks are expected to be achieved: 
1)  evaluate the necessity of parallel import licence;
2)  analyse the separate elements of the licence issuance procedure and identify its 
regulatory peculiarities;
3)  evaluate whether regulatory peculiarities identified in task II are acceptable 
according to the Eu law.
Systematic and comparative analyses together with the method of synthesis are going 
to be used in this article.
  1. Necessity of Parallel Import licence Issuance Procedure
a medicinal product may be put on the market of the Eu member State, when a 
marketing authorisation was granted at a national level in accordance with the provisions 
of the directive 2001/83/Ec16 or at the community level in accordance with the provisions 
of Regulation 2309/9317. The main purpose of the above mentioned Eu legal norms is the 
protection of public health. Thus, an obligation to obtain a marketing authorisation does 
not contradict the principle of free movement of goods.
  However, parallel trade of medicinal products occurs, when a marketing 
authorisation has already been granted by several member States and a medicinal product 
is lawfully on their market. In this case, competent authorities of member States possess 
all the documents that were submitted by the marketing authorisation holder before 
the authorisation was granted; they have evaluated these documents and have made a 
decision that a medicinal product is safe for human use. Therefore, the question is whether 
an additional licence is necessary for the parallel import product and if this question is 
answered in negative, how the safety of a parallel import product (and protection of public 
health) must be guaranteed. These issues were addressed by the Eucj in centrafarm v 
Sterling drug and de Peijper cases. 
The court in centrafarm v Sterling drug had pointed out that there is a risk to import 
defective products and, therefore, “the protection of the public against risks arising 
from defective pharmaceutical products is a matter of legitimate concern, and article 30 
[now article 36] of the treaty authorizes the member States to derogate from the rules 
concerning the free movement of goods on grounds of the protection of health and life 
of humans and animals”18. The court has also explained, that “the measures necessary 
to achieve this must be such as may properly be adopted in the field of health control 
16 directive 2001/83/Ec of the European Parliament and of the council of 6 November 2001 on 
the community code Relating to medicinal Products for Human use. [2001] oj l 311.
17 council Regulation (EEc) No 2309/93 of 22 july 1993 laying down community Procedures 
for the authorization and Supervision of medicinal Products for Human and Veterinary use 
and Establishing a European agency for the Evaluation of medicinal Products. [1993] oj l214.
18 Supra note 6, para. 27.
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<…>19. However, the court abstained from explanation what is being meant by “the 
measures necessary to achieve” and what are “properly adopted” measures. on the other 
hand, it may be observed, that the cjEu has agreed that member States can adopt some 
national rules that are aimed at the protection of human health in case of parallel import 
of medicinal products. 
The jurisprudence of the cjEu had a possibility to develop further in de Peijper. 
The facts of this case were significantly stimulating this development: a dutch importer, 
adriaan de Peijper, was prosecuted for importing a medicinal product from the uk 
without the approval of the dutch competent authorities and without possessing either 
the product marketing authorization documents or the batch records20.
The court recognised that as all relevant documents were already held by competent 
authorities, they should cooperate in making these documents available to each other21. 
If the parallelly traded and nationally authorised products were slightly different, it 
was up to the national competent authorities to investigate whether this difference was 
therapeutically significant. The only measures, which a national authority was justified 
in taking, were those intended to verify the identity of the product or sufficient similarity 
and the same therapeutical effect22. In conclusion, national competent authorities may not 
create barriers for parallel import of medicinal products by requesting parallel importers 
to satisfy the same requirements that are applicable to legal entities placing the product on 
the national market for the first time. a parallel importer is entitled to rely on medicinal 
product safety data collected at the expense of a marketing authorisation holder and the 
burden of proof rests on competent authorities. So, the cjEu has highlighted that the 
principle of relaxation of controls by national authorities in member States is closely 
related to the principle of their cooperation23.
following the de Peijper judgement, the European commission announced a 
communication on Parallel Imports of Proprietary medicinal Products in 198224, 
outlining basic principles of parallel import of medicinal products and the Eu member 
States were able to start developing simplified procedures for the parallel import license 
issuance25, 26, 27.
19 Supra note 6, para. 28.
20 Supra note 5, para. 2–8. 
21 Ibid., para. 21–24.
22 Ibid., para. 33–36.
23 kanavos, P.; Holmes, P. Pharmaceutical Parallel Trade in the UK. london: civitas, 2005, p. 12.
24 communication from the commission of 6 may 1982 on Parallel Imports of Proprietary 
medicinal Products. [1982] oj c115.
25 décret n° 2004-83 relatif aux importations de médicaments à usage humain et modifiant le 
code de la santé publique (deuxième partie: partie réglementaire). Journal Officiel de la Répu-
blique Française. 2004, NoR: SaNP0324239d.
26 Republic of malta Parallel Importation of medicinal Products Regulations. S.l.458.40.
27 medicines Evaluation Board. Parallel import: authorisation and maintenance [interactive]. 2012, 
mEB-14-3.2 [accessed on 12-09-2012]. <http://www.cbg-meb.nl/NR/rdonlyres/3497782f-
f6a8-4437-846f-433f9c460aBd/0/120529parallelimportregistratie1432EN.pdf>.
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later on, in case Commission v France, the court has also acknowledged that the lack 
of national regulatory framework (absence of a simplified license issuance procedure for 
parallel import of medicinal products for plant protection) causes a failure of a member 
State to fulfil its obligations under article 28 (now article 34 of the tfEu)28. It may be 
assumed from the above mentioned case, that a free movement of medicinal products 
creates a duty for a member State to establish a certain regulatory framework. In such a 
case, there could be a legal problem with the evaluation of lithuanian regulation just after 
the accession to the Eu. legal prerequisites for parallel trade of medicinal products for 
human use were established in 2006, when law on Pharmacy took force, i.e., two years 
after lithuania became the Eu member State. The issuance of licenses started in 2007, 
only when a specific simplified procedure was developed by the ministry of Health29. furt-
hermore, no specific procedure for parallel import of medicinal products for animal use or 
plant protection has been developed up to now. 
2.   Eligibility criteria applicable to Parallel Import medicinal  
 Products  
according to the law on Pharmacy art. 17 para. 3–4, medicinal products may be 
imported to the Republic of lithuania, when they 1) are included into the list of Parallel 
Import medicinal Products and 2) have a valid license for parallel import. Eligible for 
parallel import are only those medicinal products that are 1) identical to the medicinal 
product already registered in the Republic of lithuania or 2) sufficiently similar to it. 
medicinal products are considered sufficiently similar if they meet the following eligibility 
criteria: 
1)  the same active substance and the same salt of the active substance, the same 
ester, ether, isomer or mixtures of isomers, complexes or derivatives of an active 
substance of isomers; 
2)  the same strength;
3)  the same pharmaceutical form and administration method;
4)  the same clinical and pharmaceutical properties. Bioequivalence to a proprietary 
medicinal product with marketing authorisation in lithuania is obligatory when 
a medicinal product to-be-imported is generic. In case a product with marketing 
authorisation in lithuania and a product to-be-imported both are generics, they 
have to be bioequivalent to the same proprietary medicinal product30. 
Neither the law on Pharmacy, nor secondary legislation does not provide any clarity 
how the evaluation of sufficient similarity should be done and how the requirement for 
the products to be “the same” (in lithuanian “tas pats”) has to be interpreted in practice. 
licensing procedure that was approved by the head of State medicines control agency 
at the ministry of Health of the Republic of lithuania limits itself by stating that a senior 
28 case c-263/03, Commission v. France [2005] EcR I-05861, para. 19–20.
29 Sveikatos apsaugos ministro 2007 m. balandžio 5 d. įsakymas Nr. V-228 „dėl vaistinių prepa-
ratų lygiagretaus importo taisyklių patvirtinimo“. Valstybės žinios. 2007, Nr. 39-1456.
30 Supra note 1, art. 17, para. 3–4.
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specialist evaluates whether the medicinal product is sufficiently similar to the product 
that has a marketing authorisation in lithuania and makes a reference to two legal acts 
that have to be used for this evaluation: law on Pharmacy and the decree of the minister of 
Health on the Rules of Parallel Import of medicinal Products31. However, neither of these 
two legal acts provides any details on the processes of evaluation of sufficient similarity. 
So, it might be assumed that there are no other rules of procedure and this means that 
an evaluation of similarity and an interpretation of criteria are left upon a person, who 
is applying the law. When technically important definition of “the same” is not fixed by 
the national law, a person applying the law is free to interpret “the same” (in lithuanian 
“tas pats”) as “identical in all aspects”32. Therefore, it could be acknowledged that the 
implementation of the rules of procedure by the Smca did not solve the issue, which was 
raised by the Special Investigation Service in 2010, when it came to the conclusion that the 
regulation of license issuance procedure is not clear enough and is lacking transparency33. 
on the other hand, criteria of sufficient similarity were addressed in numerous cases 
of the cjEu. Therefore, the article further will focus on the analysis of these cases, as it 
may deepen an understanding of problems with lithuanian domestic regulation and may 
clarify whether an interpretation of “the same” as “identical in all aspects” is possible from 
the perspective of the Eu law.  
2.1. cjEu jurisprudence on Eligibility criteria applicable  
to Parallel Import medicinal Products   
In de Peijper, the court addressed a situation, when a qualitative and quantitative 
composition of a medicinal product imported by a parallel importer were different from 
those of a medicinal product that had marketing authorisation in a country of destination, 
when “the differences between the one and the other product are of such minor importance 
that it is likely that the manufacturer is applying or introducing …. these differences with 
the conscious and exclusive intention of using these differences …. in order to prevent or 
impede the possibility of the parallel importation of the proprietary medicinal product”34. De 
Peijper judgment concluded that the above mentioned variants of an already authorised 
medicinal product can be treated as similar to a product in a country of destination and 
may be imported in parallel as long as there are no differences of therapeutic significance 
between these products35. The meaning of “qualitative and quantitative differences in 
31 Valstybinės vaistų kontrolės prie lietuvos Respublikos Sveikatos apsaugos ministerijos virši-
ninko 2010 m. spalio 11 d. įsakymas Nr. P-587 „dėl lygiagrečiai importuojamų vaistinių prepa-
ratų registravimo procedūros patvirtinimo“. dokumento žymuo: 4/P-10:2010-10-1, para. 8–9. 
32 lietuvių kalbos žodynas [interactive]. Vilnius, 2011 [accessed on 05-11-2012]. <http://www.
lkz.lt/>.
33 lietuvos Respublikos Specialiųjų tyrimų tarnyba. Išvada dėl korupcijos rizikos analizės Vals-
tybinėje vaistų kontrolės tarnyboje prie Sveikatos apsaugos ministerijos [interactive]. Vilnius, 
2008 [accessed on 15-12-2012]. <http://www.stt.lt/documents/korupcijos_rizikos_analze/
VVkt_prie_Sam_kRa.pdf>, p. 22.
34 Supra note 5, para. 33.
35 Ibid., para. 34–36.
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composition” was left by the court unexplained. The explanation of it may be found in 
other cases of the cjEu. The case Smith & Nephew demands that the two products do 
not have to be identical in all respects, but they 1) should be manufactured according 
to the same formulation, 2) using the same active ingredient, and that  they 3) have the 
same therapeutic effect36. This requirement was recited in the communication of the 
commission, too37. However, there is a slight difference between the communication and 
in the cjEu ruling. It is a requirement of a common origin, that was not included into 
the communication, but actually is a part of the judgement in case Smith & Nephew and 
the judgement requires that manufacturers of both products in question should be part 
of the same group of undertakings or that they produce those medicinal products under 
agreements with the same licensor38. 
The jurisprudence of the court had a possibility to developed further in Rhŏne-
Poulenc Rorer and May § Baker judgement. according to this judgement, a medicinal 
product may be regarded as sufficiently similar if a parallel imported product has the 
same active ingredients and therapeutic effect as a product with marketing authorisation, 
but does not use the same excipient and is manufactured by a different manufacturing 
process, provided that both products have the same therapeutic effect and the marketing 
authorisations referred to above are granted to different members of the same group of 
companies and manufacturers of both medicinal products belong to the same group. 
furthermore, a parallel import licence remains valid even if a marketing authorisation 
was withdrawn in a member State of destination. according to the cjEu, a Competent 
Authority in a Member State of destination, that is granting a license for parallel trade, 
should be in a position to verify that medicinal product to be imported complies with 
requirements relating to quality, efficacy and safety, and should be in a position to ensure 
normal pharmacovigilance39. Thus, the Court followed its practice in de Peijper case and 
repeated that qualitative differences (in this case, this is a difference in excipients) do not 
preclude products to be called “sufficiently similar” for the purpose of parallel trade and their 
composition is regarded in this case as being “the same”. It may be also observed that the 
Court in Rhŏne-Poulenc Rorer and May § Baker judgement used common origin criteria 
as one of the elements that are necessary for the evaluation of sufficient similarity of 
proprietary medicinal products and clearly defined obligations of a competent authority 
that is assessing a request to grant a parallel import license.
In case Paranova Oy, the court recognised that the difference in a pharmaceutical 
form (tablets versus capsules) and composition of active substance (omeprazole acid in 
capsules versus magnesium salt of omeprazole acid in tablets) do not make these products 
incomparable for the purpose of parallel import, provided that their therapeutic effect is 
the same (both products have the same dose of the active substance, which is absorbed 
36 case c-201/94, Smith and Nephew [1996] EcR 05819, para. 26. 
37 commission of the European communities, supra note 2, p. 8.
38 Širinskienė, a.; Zalepūga, m. The Possibilities for the Implementation of measures facilitating 
and (or) Stimulating Parallel Import of medicinal Products in lithuania. Changes in Social and 
Business Environment. 2011, (4): 278.
39 case c-94/98, Rhŏne-Poulenc Rorer and May § Baker [1999] EcR I-8789, para. 48.
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at the same rate and to the same extent)40. Thus, it may be concluded that these two 
products – tablets and capsules – were regarded de facto as “sufficiently similar”, even 
though the court did not use this wording in expresis verbis. 
Several major changes in a licence issuance procedure occurred after the Kohlpharma 
case. Here, the court addressed the requirement of the common origin that was used by 
member States for the comparison of “sufficient similarity”. However, despite the existing 
practice, the court refused to acknowledge the requirement of the common origin as a 
necessary requirement for the evaluation of a sufficient similarity of a medicinal product 
to be imported and pointed out that “In the case where an application for a marketing 
authorisation for a medicinal product is submitted with reference to a medicinal product 
that has already been authorised;
– the medicinal product which is the subject of the application is imported from a 
member State in which it has obtained a marketing authorisation;
– the assessment of safety and efficacy carried out for the medicinal product which 
is already authorised can be used in the application for a marketing authorisation 
for the second medicinal product without the risk to public health.” 41
according to the court, articles 34 and 36 of the tfEu preclude the application 
being rejected solely on the ground that the two medicinal products do not have a common 
origin42. However, the court suggested that a common origin can be “an important 
element” in determining comparability of two products, when a competent authority 
in a member State has to evaluate whether the safety and efficacy assessment carried out 
for the medicinal product, which has already been authorised in a member State, can 
be applied to the product that is going to be imported43. In such a way, the Kohlpharma 
judgement opened the gate for the parallel import of generic medicinal products. 
on the other hand, this judgment created uncertainty that is widely discussed among 
scientists44. There are even doubts if mutual recognition is needed for generic medicinal 
products, when a product approved in one member State could be placed on the market 
of another one by obtaining a simplified license for parallel import that is based on the 
approval received by the marketing authorisation holder of the proprietary product in 
a member State of destination45. on the other hand, the judgement did not tackle the 
issue of pharmacovigilance and, therefore, it is not clear how pharmacovigilance should 
be guaranteed when common origin of the product is missing.
40 Supra note 8, para. 14–15. It should be noted, that the difference in active substance was 
introduced by the manufacturer because of technical reasons only. It was easier to manufacture 
tablets than capsules since the salt dissolves more easily in water and is more stable.
41 Supra note 7,  para. 21.
42 Ibid.
43 Ibid., para. 17.
44 kyle, m. k. Strategic Responses to Parallel trade. NBER Working Paper Series. cambridge: 
National Bureau of Economic Research, 2007, p. 10.
45 faus, j. Similarity of medicinal Products and free movement of goods: Is Parallel distribution 
the Beginning of the End for mutual Recognition? Journal Of Generic Medicines. 2005, 3(1): 
38–46.
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a common origin was also addressed in case Commission of the European Communities 
v French Republic. This case relates to plant protection products. The law of france required 
that both a product imported in parallel and a product with marketing authorization in 
france should have a common origin. The commission considered that this requirement 
is a restriction on free movement of goods, which is contrary to article 34 of the tfEu. 
The commission in its decision explicitly relied on the Kohlpharma judgement. However, 
the cjEu pointed out the differences between the Eu legislation applicable to medicinal 
products for human use and to plant protection products respectively and has made a 
conclusion that a requirement of common origin for plant protection products cannot 
be considered as contrary to article 34 of the tfEu46.  Thus, different levels of regulation 
of various types of medicinal products may result in different rules for the evaluation of 
their sufficient similarity. However, the questions raised by the Kohlpharma judgement 
and the emphasis on a common origin in the judgement Commission of the European 
Communities v French Republic let us presume that there is a huge possibility of future 
litigations and that the court will probably come back to the issue of a common origin 
when addressing sufficient similarity.
2.2.  Eligibility criteria applicable to Parallel Import medicinal  
 Products in lithuanian National law and Possible Barriers  
 for Parallel trade 
turning back to the domestic law, it should be observed that it took nearly 5 years 
for lithuania to start using the Kohlpharma judgement as a basis for legislation. debates 
about the implementation of this judgement started in 2010 with the new draft of the 
law on Pharmacy that took force in january 201247. However, the problems with parallel 
import of generic medicinal products still remain. Systematic analysis of articles 17 and 
11 of the law on Pharmacy shows that there could be some doubts about the legitimacy 
of parallel trade of generic medicinal products, as article 17 paragraph 4 part 1 is left 
unchanged and the same salt of the active substance, the same ester, ether, isomer or 
mixtures of isomers, complexes or derivatives of an active substance of isomers are still 
required during evaluation of sufficient similarity. This may create barriers for parallel 
import of some generic products, because according to the article 11 paragraph 8, a 
proprietary medicinal product and a bioequivalent generic product may have different 
salts, esters, ethers, etc. 
The above analysis of the jurisprudence of the cjEu (especially the position of the 
court in cases Paranova Oy and De Peijper) also supports the conclusion that barriers for 
parallel trade may occur with the national requirement for “the same strength” and “the 
46 Supra note 28, para. 20, 30–40.
47 lietuvos Respublikos farmacijos įstatymo 2, 4, 9, 12, 14, 17, 20, 23, 27, 33, 39, 55, 57, 62 ir 64 
straipsnių pakeitimo ir įstatymo priedo papildymo įstatymo projektas [interactive]. Vilnius, 
2010-07-01 [accessed on 02-03-2013]. <http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_ 
l?p_id=377399>.
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same pharmaceutical form”48, when strength and form have no influence on a therapeutic 
effect and safety of a product. furthermore, the interpretation of “sufficient similarity” in 
the domestic law may be one of the reasons leading to a low number of parallel import 
medicinal products in lithuania, as it limits a number of products that are eligible for 
parallel trade. In practise, there have already been cases, when a parallel import licence 
was refused for products that are put on the market as “powder with solvent” in country of 
export and marketed as “powder” in lithuania49. It should be observed that both products 
have had the same therapeutic effect. 
 on the other hand, while reflecting potential problems with the requirement of “the 
same strength” and “the same form” in the domestic law, it should be noted that marketing 
authorisation holders take different measures aimed at limiting parallel import, e.g.,  in 
1989-1993, company Bayer introduced 24 different versions of the medicinal product 
called Adalat in the Eu countries (all versions had different form and/or strength) with 
the aim to eliminate the possibility that those products will be evaluated as sufficiently 
similar for the purpose of parallel trade50. Therefore, the review of the domestic law and 
elimination of those norms that are inconsistent with the Eu law and can aggravate the 
evaluation of sufficient similarity providing surplus requirements are inevitable measures 
that may facilitate parallel trade and help to increase the availability of low price medicinal 
products.  
3. “Reasonable time” and “accessibility” of Parallel Import  
license Procedure 
according to the cjEu, a national procedure that regulates the issuance of licenses 
for parallel import of medicinal products in a member State of destination is supposed 
to be easily accessible (in french facilement accessible) and should “last a reasonable 
time” (in french dans un délai raisonnable)51. However, the court has never explained in 
expresis verbis how accessibility and a reasonable time of the procedure are understood.
Reasonable time of the procedure was addressed by the European commission in 
its communication only. The European commission pointed out that directive 2001/83 
defines a 90 days period, within which a member State may decide on a recognition of a 
marketing authorisation issued by another member State52. Therefore, the commission 
suggests that the period of 45 days may be a reasonable time limit for a simplified procedure 
in case of parallel import. The same time limit of the procedure is defined by the national 
law53. This period begins when the competent authority (State medicines control agency 
48 Supra note 1, art. 17, para. 3–4.
49 lygiagretaus importo vaistinių preparatų lietuvoje apžvalga. Skirta lietuvos Respublikos Sei-
mo nariams. Vilnius: lexano, 2011.
50 Supra note 44,  p. 12.
51 Supra note 28, para. 21; Supra note 9, para. 45–49.
52 Supra note 2, p. 7.
53 Supra note 1, art. 17, para. 7.
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in lithuania) accepts an application submitted according to the requirements established 
by the minister of Health. The time spent by an applicant for provision of additional 
documents and necessary explanations required by the State medicines control agency in 
not included in a 45 days period. No other time limit is defined in a secondary legislation, 
e.g., it is not clear in how many days the State medicines control agency is obliged to 
review an application and make a decision that this application is submitted according 
to the national requirements; it is not clear when the State medicines control agency 
has to contact a competent authority in a member State of origin. The time needed for a 
communication with a competent authority in a member State of origin may also exceed 
a period of 45 days, as the Eu law does not define an exact number of days that is given to 
a competent authority in a member State of origin for the preparation of documents that 
need to be send for a review in a member State of destination. on the other hand, only 
two persons at the State medicines control agency are responsible for the evaluation of 
medicinal products, which are to be imported, and the issuance of licenses. furthermore, 
parallel import related duties are not their only duties at the State medicines control 
agency54. Thus, the capacities of the staff are rather limited. Therefore, the 45 days period 
is much longer in practice and in some instances it is significantly longer than the period 
needed for a marketing authorisation issuance procedure (e.g., a simplified procedure may 
take up to 580 days)55. These facts suggest that domestic regulation of a license issuance 
procedure needs to be improved by adding specific deadlines, e.g., the ones for formal 
evaluation of documents submitted. on the other hand, administrative measures at the 
State medicines control agency can be also reconsidered, as a limited number of staff 
employed and its constant overload with other duties may influence the functionality of 
an existing procedure. 
 conclusions
1. a simplified parallel import license issuance procedure is a legitimate procedure 
based on article 36 of the tfEu, as it ensures that parallel import products are not risky 
to the health and life of humans. due to the need to ensure the same therapeutic effect, 
a number of parallel import medicinal products is limited to products that are regarded 
as identical or sufficiently similar if compared with the products marketed in a member 
State of destination.
2. The Eucj has developed a set of rules used for the comparison of sufficient 
similarity of products to be imported. Products having the same active substance, the 
same formulation and the same therapeutic effect are undoubtedly treated as sufficiently 
similar. However, it may be observed in the jurisprudence that wording “the same” does 
not mean “identical in all aspects” and there may be cases, when differences in an active 
substance (e.g., acid and salt of that acid) and in a pharmaceutical form (e.g., tablets 
54 darbuotojų atliekamos funkcijos ir specialieji reikalavimai jų pareigybei [interactive]. Vilnius, 
2013 [accessed on 04-03-2013]. <http://www.vvkt.lt/lit/VVkt-darbuotoju-atliekamos-funkci-
jos-ir-specialieji-reikalavimai/800>.
55 Supra note 48.
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versus capsules) or in a quantity of an active substance may be regarded to be of minor 
importance and, therefore, products are treated as sufficiently similar for the purpose of 
parallel trade, provided that their therapeutic effect remains identical.  
3. The Eu law and the cjEu jurisprudence were not taken into consideration during 
the development of sufficient similarity criteria in lithuania. This especially applies to the 
requirements of the same pharmaceutical form and the same strength. a lack of detailed 
secondary legislation together with administrative problems, such as a lack of personnel, 
may reduce the accessibility of the procedure and challenge the implementation of the 
requirement that the procedure should last “a reasonable time”. Therefore, legislative 
measures should be taken in order to make a license issuance procedure more flexible and 
sufficient similarity criteria need to be adapted to the jurisprudence of the cjEu. 
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REIkalaVImaI žmoguI SkIRtų VaIStINIų PREPaRatų  
lYgIagREtauS ImPoRto lEIdImų IŠdaVImuI IR galImoS  
lYgIagREtauS ImPoRto į lIEtuVoS RESPuBlIką klIūtYS
mindaugas Zalepūga
mykolo Romerio universitetas, lietuva
Santrauka. Lygiagretus vaistinių preparatų importas – kitoje EEE valstybėje regist-
ruoto vaistinio preparato, kuris yra tapatus Lietuvos Respublikoje jau registruotam vaisti-
niam preparatui ar pakankamai į jį panašus, įvežimas į Lietuvos Respubliką nesinaudojant 
vaistinio preparato rinkodaros teisės turėtojo platinimo tinklu – Lietuvoje yra įmanomas 
nuo tada, kai Lietuva tapo ES nare. Tačiau iki šiol lygiagretus vaistinių preparatų importas 
nėra paplitęs. Antra vertus, straipsnyje atkreipiamas dėmesys į tai, jog lygiagretus vaistinių 
preparatų importas kyla iš laisvos prekybos principo. Šio principo taikymą farmacijos sek-
toriuje valstybės narės interpretuoja labai skirtingai. Kaip rodo Europos Sąjungos Teisingu-
mo Teismo praktika, toks skirtingas interpretavimas lemia ir prekybos laisvės suvaržymus, 
ypač tada, kai valstybėse narėse yra priimami sprendimai dėl lygiagretaus importo leidimų 
išdavimo. Dėl to straipsnio tyrimų objektu pasirinktas lygiagretaus vaistinių preparatų im-
porto leidimų išdavimo reguliavimas. Straipsnio tikslas – nustatyti ir nagrinėti lygiagretaus 
vaistinių preparatų leidimų išdavimo reguliavimo ypatumus, įvertinant, ar jie nesukuria 
kliūčių lygiagrečiam vaistinių preparatų importui į Lietuvos Respubliką.
nodaros reguliavimo problemos lietu-
voje. Taikomieji tyrimai – visuomenės 
kaitai: mokslinių straipsnių rinkinys. 
2011, 6: 128–135.  
Širinskienė, a; Zalepūga, m. Perpakavi-
mo įtakos lygiagrečiai importuojamų 
vaistinių preparatų kokybei vertinimas 
Europos Sąjungos teisingumo teismo 
jurisprudencijoje. Sveikatos mokslai. 
2011, 1(73): 3854–3860. 
State agency of medicines of latvia. Re-
gister of Human medicines [interacti-





Sveikatos apsaugos ministro 2007 m. ba-
landžio 5 d. įsakymas Nr. V-228 „dėl 
vaistinių preparatų lygiagretaus impor-
to taisyklių patvirtinimo“. Valstybės ži-
nios. 2007, Nr. 39-1456. 
treaty on the functioning of the Euro-
pean union (consolidated version). 
[2012] oj c326. 
Valstybinė vaistų kontrolės tarnyba prie 
lietuvos Respublikos Sveikatos ap-
saugos ministerijos. lygiagrečiai plati-
namų lietuvos Respublikoje vaistinių 
preparatų sąrašas [interactive]. Vil-
nius, 2013 [accessed on 11-09-2013]. 
<http://i2.alfi.lt/46/68/81.jPg>. 
Valstybinės vaistų kontrolės prie lietuvos 
Respublikos Sveikatos apsaugos minis-
terijos viršininko 2010 m. spalio 11 d. 
įsakymas Nr. P-587 „dėl lygiagrečiai 
importuojamų vaistinių preparatų re-
gistravimo procedūros patvirtinimo“. 
dokumento žymuo: 4/P-10:2010-10-1. 
Societal Studies. 2013, 5(4): 1190–1205. 1205
Siekiant užsibrėžto tikslo straipsnyje pirmiausiai analizuojama, ar valstybėse narėse 
taikoma leidimų sistema yra būtina ir priimtina ES teisės atžvilgiu. Padarius išvadą, jog 
ši sistema nesukelia ES teisės pažeidimo, nagrinėjami atskiri leidimų sistemos elementai, 
daugiausiai dėmesio skiriant vaistinių preparatų pakankamo panašumo vertinimo krite-
rijų analizei. Straipsnyje, remiantis Europos Sąjungos Teisingumo Teismo jurisprudencija, 
atkreipiamas dėmesys į tai, jog atskirų pakankamo panašumo vertinimo kriterijų (pvz., 
identiškos vaistinio preparato formos, identiško veikliosios medžiagos kiekio reikalavimas) 
taikymas gali pažeisti laisvo prekių judėjimo principą. Taip pat analizuojami ir leidimų 
išdavimo terminai bei administracinio pobūdžio apribojimai. 
Daroma išvada, jog rengiant nacionalinės teisės aktus, reguliuojančius lygiagretaus 
vaistinių preparatų importo leidimo išdavimo sistemą, o ypač nustatant pakankamo pa-
našumo kriterijus, nebuvo atsižvelgta į Europos Sąjungos Teisingumo Teismo praktiką. 
Išsamaus poįstatyminio reguliavimo trūkumas drauge su administracinėmis problemomis 
– personalo stygiumi – gali apsunkinti lygiagretaus vaistinių preparatų leidimų išdavimo 
prieinamumą ir kelti problemų siekiant, kad leidimai būtų išduodami „per protingą laiko 
tarpą“, kaip kad reikalauja Europos Sąjungos Teisingumo Teismas. Todėl įstatymų leidėjas 
turėtų imtis priemonių, kurios užtikrintų tinkamą procedūros prieinamumą. Taip pat, at-
sižvelgiant į Europos Sąjungos Teisingumo Teismo praktiką, reikėtų svarstyti apie Lietuvos 
Respublikos farmacijos įstatymo pataisas, kuriomis būtų įgyventinti minėtojo teismo spren-
dimai, susiję su vaistinių preparatų pakankamo panašumo vertinimu.
Reikšminiai žodžiai: lygiagretus importas, leidimas, vaistinis preparatas, farmacijos 
teisė, ES teisė.
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